TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02890927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio-geriatric co-management
Description: A comprehensive geriatric assessment on admission will stratify patients in groups:~1. Low risk patients are expected to do well and will not receive co-management.~2. Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~3. High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.
Study: NCT02721225

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pocari-Sweat
Description: Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
Study: NCT02338739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REC; Outreach if Failure
Description: Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REC; SMS + Voucher if Failure
Description: Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REC; Navigator if Failure
Description: REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; Outreach if Failure
Description: SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; Outreach if Failure; Stop SMS if Success
Description: SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; SMS+Voucher if Failure
Description: SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; SMS+Voucher if Failure; Stop SMS if Success
Description: SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
Study: NCT01817400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.
Study: NCT02338739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; Navigator if Failure
Description: SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; Navigator if Failure; Stop SMS if Success
Description: SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; Outreach if Failure
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; Outreach if Failure; Stop Voucher if Success
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; SMS+Voucher if Failure
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; SMS+Voucher if Failure; Stop Voucher if Success
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; Navigator if Failure
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; Navigator if Failure; Stop Voucher if Success
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
Study: NCT00333541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using internet/E-mail for follow-up
Description: follow-up via email link to survey
Study: NCT02104609

Intervention type: DRUG
Intervention: Levonorgestrel 1.5mg by mouth once
Description: Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8

Intervention type: DRUG
Intervention: Levonorgestrel 1.5mg by mouth once
Description: Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8

Intervention type: DRUG
Intervention: Levonorgestrel 1.5mg by mouth once
Description: Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
Study: NCT01817400

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vascepa - Fish Oil
Description: We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
Study: NCT01249092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
Study: NCT01809808

Intervention type: PROCEDURE
Intervention: Surgery for acromegaly
Description: (non-experimental) standard procedure
Study: NCT02326662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
Study: NCT03904173

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-parameter tests
Description: Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
Study: NCT00860743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail
Description: 120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
Study: NCT02902887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Controlled Intermittent Alternate Occlusion (CIAO ) glasses
Description: Monitored CIAO therapy glasses
Study: NCT02208752

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercises
Description: exercise program on strengthening the rotator cuff muscles and motor control of the scapula
Study: NCT00932126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03758309
Description: Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
Study: NCT00066365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: thoracotomy
Study: NCT02208752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: exercise program on strengthening the rotator cuff muscles and motor control of the scapula
Study: NCT04027881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Together and REad
Description: STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
Study: NCT00066365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: thoracotomy
Study: NCT01809808

Intervention type: DRUG
Intervention: Medications for acromegaly
Description: (non-experimental) standard procedure
Study: NCT00764296

Intervention type: OTHER
Intervention: no treatment
Description: collection of samples of wound biofilm in Acute and Chronic Wounds

Intervention type: OTHER
Intervention: no treatment
Description: collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
Study: NCT01809808

Intervention type: DIAGNOSTIC_TEST
Intervention: Total body magnetic resonance imaging
Description: Subjects will undergo total body MRI with spectroscopy of the muscle and liver before and 3-6 months, 12 and 24 months after surgery or medical therapy for acromegaly.

Intervention type: DIAGNOSTIC_TEST
Intervention: Total body magnetic resonance imaging
Description: Subjects will undergo total body MRI with spectroscopy of the muscle and liver before and 3-6 months, 12 and 24 months after surgery or medical therapy for acromegaly.
Study: NCT02244931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servomatic™ assisting device
Description: Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
Study: NCT01809808

Intervention type: PROCEDURE
Intervention: Adipose Tissue Biopsy
Description: Subjects will undergo biopsy of subcutaneous adipose tissue before and 12 and 24 months after surgery or medical therapy for acromegaly.

Intervention type: PROCEDURE
Intervention: Adipose Tissue Biopsy
Description: Subjects will undergo biopsy of subcutaneous adipose tissue before and 12 and 24 months after surgery or medical therapy for acromegaly.
Study: NCT03020173

Intervention type: OTHER
Intervention: Laboratory study
Description: Laboratory analysis to determine composition of granulosa and oocytes

Intervention type: OTHER
Intervention: Laboratory study
Description: Laboratory analysis to determine composition of granulosa and oocytes
Study: NCT02146664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
Study: NCT04553302

Intervention type: OTHER
Intervention: This study does not contain any intervention.
Description: This study does not contain any intervention.

Intervention type: OTHER
Intervention: This study does not contain any intervention.
Description: This study does not contain any intervention.

Intervention type: OTHER
Intervention: This study does not contain any intervention.
Description: This study does not contain any intervention.
Study: NCT03944031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372689
Description: Administered orally.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]LSN3316612
Description: Administered IV.
Study: NCT03887546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle trainer
Description: The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory exercise
Description: Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
Study: NCT03094104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT00143689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine
Description: See Detailed Description.
Study: NCT01289119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study: NCT02758704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High stress
Description: Generation of a stressful environment during a neonatal intubation procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low stress
Description: Absence of stressful stimuli during neonatal intubation procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation on mannequin
Description: Endotracheal intubation will take place at the simulation centre on a mannequin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation on mannequin
Description: Endotracheal intubation will take place at the simulation centre on a mannequin.
Study: NCT03542123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroTronik CANS Therapy® System
Description: The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
Study: NCT01289119

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to alogliptin
Description: Alogliptin placebo-matching tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to alogliptin
Description: Alogliptin placebo-matching tablets.
Study: NCT04203498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Description: Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
Study: NCT02244931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servomatic™ assisting device
Description: Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E.Motion© assisting device
Description: E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E.Motion© assisting device
Description: E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
Study: NCT04203498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
Study: NCT01289119

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to alogliptin
Description: Alogliptin placebo-matching tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Stable metformin dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable metformin dose

Intervention type: DRUG
Group type: OTHER
Intervention: Pioglitazone
Description: Stable pioglitazone dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Stable pioglitazone dose
Study: NCT02313441

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Remote Ischemic Pre-Conditioning
Description: The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Pre-Conditioning
Description: The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
Study: NCT03787706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Patients will receive dry needling over active trigger points in the upper trapezius muscle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
Study: NCT02987543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 300 mg (2x 150 mg tablets) twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzalutamide
Description: 160 mg (4 x 40 mg capsules) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone acetate
Description: 1,000 mg (4 x 250 mg tablets) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone acetate
Description: 1,000 mg (2 x 500 mg tablets) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzalutamide
Description: 160 mg (4 x 40 mg tablets) once daily